Quarterly Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7595769

Concept As at
2022-06-30
2022-01-01 to
2022-06-30
As at
2021-12-31
2021-01-01 to
2021-06-30
As at
2021-06-30
As at
2020-12-31
Quarterly statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-569,108,000 JPY
-649,015,000 JPY
Depreciation
155,000 JPY
3,054,000 JPY
Interest and dividend income
-287,000 JPY
-241,000 JPY
Interest expenses
1,937,000 JPY
2,109,000 JPY
Foreign exchange losses (gains)
-82,550,000 JPY
-27,452,000 JPY
Decrease (increase) in trade receivables
321,697,000 JPY
-40,168,000 JPY
Decrease (increase) in inventories
251,000 JPY
-507,000 JPY
Other, net
-51,383,000 JPY
33,395,000 JPY
Subtotal
-719,719,000 JPY
-588,619,000 JPY
Interest and dividends received
154,000 JPY
136,000 JPY
Interest paid
-2,189,000 JPY
-2,387,000 JPY
Income taxes paid
-728,000 JPY
-3,719,000 JPY
Net cash provided by (used in) operating activities
-722,482,000 JPY
-594,589,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-635,000 JPY
-743,000 JPY
Proceeds from sale of investment securities
JPY
486,000 JPY
Net cash provided by (used in) investing activities
20,841,000 JPY
-327,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
100,000,000 JPY
100,000,000 JPY
Repayments of long-term borrowings
-72,220,000 JPY
-66,672,000 JPY
Proceeds from issuance of shares
JPY
3,085,224,000 JPY
Purchase of treasury shares
-28,000 JPY
JPY
Net cash provided by (used in) financing activities
29,599,000 JPY
3,148,769,000 JPY
Effect of exchange rate change on cash and cash equivalents
76,061,000 JPY
25,304,000 JPY
Net increase (decrease) in cash and cash equivalents
-595,979,000 JPY
2,579,157,000 JPY
Cash and cash equivalents
2,613,656,000 JPY
3,209,635,000 JPY
4,402,007,000 JPY
1,822,850,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.